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Background: Both angiotensin II type I receptor blockers (ARBs) and calcium channel blockers (CCBs) are widely
used antihypertensive drugs. Many clinical studies have demonstrated and compared the organ-protection effects
and adverse events of these drugs. However, few large-scale studies have focused on the effect of these
drugs as monotherapy on laboratory parameters. We evaluated and compared the effects of ARB and
CCB monotherapy on clinical laboratory parameters in patients with concomitant hypertension and type 2
diabetes mellitus.
Methods: We used data from the Clinical Data Warehouse of Nihon University School of Medicine obtained
between Nov 1, 2004 and July 31, 2011, to identify cohorts of new ARB users (n = 601) and propensity-score
matched new CCB users (n = 601), with concomitant mild to moderate hypertension and type 2 diabetes
mellitus. We used a multivariate-adjusted regression model to adjust for differences between ARB and CCB
users, and compared laboratory parameters including serum levels of triglyceride (TG), total cholesterol (TC),
non-fasting blood glucose, hemoglobin A1c (HbA1c), sodium, potassium, creatinine, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), hemoglobin and hematocrit, and
white blood cell (WBC), red blood cell (RBC) and platelet (PLT) counts up to 12 months after the start of ARB
or CCB monotherapy.
Results: We found a significant reduction of serum TC, HbA1c, hemoglobin and hematocrit and RBC count
and a significant increase of serum potassium in ARB users, and a reduction of serum TC and hemoglobin in
CCB users, from the baseline period to the exposure period. The reductions of RBC count, hemoglobin and
hematocrit in ARB users were significantly greater than those in CCB users. The increase of serum potassium
in ARB users was significantly greater than that in CCB users.
Conclusions: Our study suggested that hematological adverse effects and electrolyte imbalance are greater
with ARB monotherapy than with CCB monotherapy.
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Angiotensin II type I receptor blockers (ARBs) are well
established antihypertensive drugs that are frequently used
as the first-line drug for hypertension. Recently, there has
been a focus on the beneficial effects of ARBs other than
their antihypertensive effect, such as reduction of protein-
uria [1] and decreased heart failure risk in patients with
chronic heart failure [2]. Calcium channel blockers (CCBs)
are also widely used first-line antihypertensive drugs. CCBs
are known to decrease the risk of coronary heart disease
and non-fatal stroke in patients with hypertension [3], and
to decrease proteinuria in patients with chronic renal
disease [4]. While ARBs and CCBs have a favorable effect
on blood pressure and decrease the risk of several com-
plications, these drugs have some adverse effects.
Renin-angiotensin system inhibitors including ARBs are
known to cause hyperkalemia [5] and anemia [6,7]. CCBs
are known to cause edema [8].
Hypertension and type 2 diabetes mellitus are con-
ditions that frequently coexist [9], both of which carry an
increased risk of cardiovascular and renal disease.
Hypertension significantly hastens the progression of
diabetic nephropathy and increases the risk of cardio-
vascular events or death in patients with diabetes. On
the contrary, lowering blood pressure decreases albumin-
uria in type 2 diabetes [10,11]. On the other hand, ARBs
have a beneficial effect that prevents the new-onset of
diabetes [12], and there has been a recent focus on the
effect of ARBs on glucose metabolism. We demonstrated
a favorable effect of ARB monotherapy on glucose
metabolism in non-diabetic hypertensive patients [13].
Whether ARBs have a favorable effect on laboratory
parameters, including parameters of glucose metabolism
in diabetic hypertensive patients, may be of clinical
significance.
Some randomized clinical studies have compared the
adverse effects of ARBs and CCBs. [14-16]. However,
those studies usually focused on the adverse events of
antihypertensive drugs, and there are few large-scale
studies focused on the effects of the drugs on laboratory
parameters. In addition, few studies have targeted ARB
and CCB monotherapy using a clinical database reflect-
ing 'real-world' data. Therefore, in this study, we evalu-
ated and compared the effects of ARB and CCB
monotherapy on laboratory parameters, including para-
meters of lipid metabolism, glucose metabolism, renal
function, hepatic function and hematological analysis
in patients with concomitant hypertension and type 2
diabetes mellitus, using a clinical database.
Materials and methods
Data source
This was a retrospective database study using the
Nihon University School of Medicine (NUSM) ClinicalData Warehouse (CDW). NUSM's CDW is a centralized
data repository that integrates separate databases,
including an order entry database and a laboratory
results database, from the hospital information systems
at three hospitals affiliated to NUSM. The prescribing
data of over 0.5 million patients are linked longitudinally
to detailed clinical information such as patient demo-
graphics, diagnosis, and laboratory results data. The
schema of NUSM's CDW has been reported by
Takahashi et al. [17].
Study population
For this study, we identified type 2 diabetes mellitus
patients with mild to moderate hypertension aged over
20 years, who had been newly treated with ARB mono-
therapy (n = 922) or dihydropyridine CCB monotherapy
(n = 731) for at least two months between Nov 1, 2004
and July 31, 2011. The antihypertensive drugs used in
the ARB and CCB monotherapy groups are listed in
Table 1. We compared new users of ARBs (n = 601) with
propensity-score matched samples of new CCB users
(n = 601). We excluded patients who had been treated
with other antihypertensive drugs (ARB combination
drug, angiotensin-converting enzyme inhibitor (ACEI),
diuretic, alpha-blocker, beta-blocker, alpha and beta-
blocker, alpha-agonist, reserpine, vasodilator, or renin
inhibitor) during the study period. The experimental
protocol was approved by the Ethical Committee of
Nihon University School of Medicine.
Exposure and measurements
The baseline measurement period (non-exposure period)
was defined as within 12 months before the start of ARB
or CCB monotherapy. The exposure period (outcome
measurement period) was defined as between 2 and
12 months after the start of ARB or CCB monotherapy.
The mean exposure of ARB users and CCB users was
243.2 days and 242.1 days, respectively. Laboratory data,
including serum levels of triglyceride (TG), total choles-
terol (TC), non-fasting blood glucose, hemoglobin A1c
(HbA1c), creatinine, sodium, potassium, alanine amino-
transferase (ALT), aspartate aminotransferase (AST), and
gamma-glutamyltransferase (GGT), hemoglobin, hema-
tocrit, and white blood cell (WBC), red blood cell (RBC)
and platelet (PLT) counts, were collected for each individ-
ual at the date nearest the start of ARB or CCB mono-
therapy in the baseline period, and at the date nearest
12 months after the start of ARB or CCB monotherapy in
the exposure period.
Data elements
For each patient, we collected information of patient
demographics (age and sex), medical history, use of medi-
cation, and laboratory results. Medical history included
Table 1 Antihypertensive drugs
Category Generic name Trade name No. of cases of monothrapy
Before PSmatching After PSmatching
ARBs
candesartan cilexetil Blopress 289 200
losartan potassium Nu-lotan 154 87
olmesartan medoxomil Olmetec 177 113
telmisartan Micardis 141 91
valsartan Diovan 161 110
CCBs
amlodipine besilate Norvasc, Amlodin 355 277
azelnidipine Calblock 46 38
benidipine hydrochloride Coniel 82 66
cilnidipine Atelec, Cinalong 41 36
manidipine hydrochloride Calslot 25 21
nicardipine hydrochloride Perdipine 17 13
nifedipine Adalat, Herlat, Sepamit 133 110
nilvadipine Nivadil 30 24
others (barnidipine hydrochloride, efonidipine
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heart disease (I20-I25), other heart disease (I30-I52), liver
disease (K70-K77), kidney disease (N00-N19), gout (M10),
thyroid gland disorder (E00-E07), rheumatoid arthritis
(M05-M06), hyperlipidemia (E78.0-E78.5), or proteinuria
diagnosed in the 365 days preceding the first date of
prescription of ARB or CCB. Drugs used during the
60 days before the start of ARB or CCB monotherapy
included hypoglycemic drugs (including insulin and oral
hypoglycemic drugs), lipid-lowering drugs (including
statins, fibrates and other lipid-lowering drugs), diuretics,
immunosuppressive drugs, gout drugs, potassium prepara-
tions, antipsychotics, chemotherapeutic drugs, steroids,
non-steroidal anti-inflammatory drugs (NSAIDs), proton
pump inhibitors, histamine H2 receptor blockers and
thyroid drugs.
Statistical analysis
The ARB user group and CCB user group were matched
by propensity score using a 5-digit, greedy 1:1 matching
algorithm [18-20]. This method is the standard method
to reduce bias by balancing covariates between settings,
and has been used in many reports. To generate the
propensity score, we used covariates including age, sex,
medical history (cerebrovascular disease, ischemic heart
disease, other heart disease, liver disease, kidney disease,
gout, thyroid gland disorder, rheumatoid arthritis,
hyperlipidemia and proteinuria) and previous drugs
(hypoglycemic drugs including insulin and oralhypoglycemic drugs, lipid-lowering drugs including
statins, fibrates and other lipid-lowering drugs, diuretics,
immunosuppressive drugs, gout drugs, potassium
preparations, antipsychotics, chemotherapeutic drugs,
steroids, NSAIDs, proton pump inhibitors, histamine H2
receptor blockers and thyroid drugs), as listed in Table 2.
We compared the prevalence of all baseline covariates
before and after propensity score matching using t-test
for continuous variables and chi-squared test for
categorical data. After propensity score matching, covari-
ance-adjusted and unadjusted generalized linear models
(Dunnett-Hsu post-hoc analysis) were fitted to compare
the mean values of laboratory parameters at baseline and
during the exposure period in ARB users and CCB users,
and were used to compare the mean change from the
baseline value to the exposure value in ARB users and
CCB users. The covariates that were used in the adjusted
model included age, sex, medical history and previous
medication, as listed in Table 2. All reported P values of
less than 0.05 were considered to indicate statistical
significance. All statistical analyses were performed with
SAS software, version 9.1.3 (SAS Institute Inc., Cary, NC).
Results
Table 2 shows the characteristics of the patients who had
been treated with ARB monotherapy or CCB monother-
apy, before and after propensity score matching. Before
propensity score matching, ARB users were more likely
to have thyroid disease, kidney disease, proteinuria and
Table 2 Baseline characteristics before and after propensity score matching
Characteristics Before matching After macthing
ARB users CCB users p value ARB users CCB users (n = 601)
(n = 922) (n = 731) (n = 601) p value
Age (mean, SE) 61.7 ± 0.4 66.8 ± 0.35 <.0001 * 65.5 ± 0.4 65.6 ± 0.39 0.8268
Age over 75 years 130 (14.1%) 158 (21.6%) <.0001 * 110 (18.3%) 113 (18.8%) 0.8238
Women 316 (34.3%) 281 (38.4%) 0.0798 224 (37.3%) 225 (37.4%) 0.9525
Medical history
Cerebrovascular disease 254 (27.5%) 208 (28.5%) 0.6837 170 (28.3%) 185 (30.8%) 0.3429
Ischemic heart disease 317 (34.4%) 297 (40.6%) 0.009 * 228 (37.9%) 233 (38.8%) 0.7668
Other heart disease 208 (22.6%) 193 (26.4%) 0.0703 156 (26.0%) 149 (34.8%) 0.6427
Gout 28 (3.0%) 43 (5.9%) 0.0046 * 25 (4.2%) 25 (4.2%) 1
Thyroid disorder 266 (28.9%) 155 (21.2%) 0.0004 * 141 (23.5%) 142 (23.6%) 0.9458
Rheumatoid arthritis 85 (9.2%) 68 (9.3%) 0.9538 48 (8.0%) 51 (8.5%) 0.753
Liver disease 481 (52.2%) 404 (55.3%) 0.2098 327 (54.4%) 316 (52.6%) 0.5247
Kidney disease 688 (74.6%) 483 (66.1%) 0.0001 * 407 (67.7%) 411 (68.4%) 0.8046
Hyperlipidemia 860 (93.3%) 678 (92.7%) 0.6764 559 (93.0%) 561 (93.3%) 0.819
Proteinuria 463 (50.2%) 298 (40.8%) 0.0001 * 255 (42.4%) 256 (42.6%) 0.9535
Previous drugs
Hypoglycemic drugs 226 (24.5%) 188 (25.7%) 0.574 148 (24.6%) 156 (26.0%) 0.5955
Insulin 79 (8.6%) 44 (6.0%) 0.0498 * 36 (6.0%) 42 (7.0%) 0.4823
Oral hypoglycemic drugs 171 (18.5%) 160 (21.9%) 0.0918 126 (21.0%) 129 (21.5%) 0.8324
Lipid-lowering drugs 339 (36.8%) 237 (32.4%) 0.0655 201 (33.4%) 200 (33.3%) 0.9512
Statin 286 (31.0%) 200 (27.4%) 0.1048 171 (28.5%) 169 (28.1%) 0.8981
Fibrate 36 (3.9%) 29 (4.0%) 0.9481 21 (3.5%) 23 (3.8%) 0.7587
Other lipid-lowering drugs 30 (3.3%) 23 (3.1%) 0.902 18 (3.0%) 18 (3.0%) 1
Diuretics 7 (0.8%) 1 (0.1%) 0.0701 1 (0.2%) 1 (0.2%) 1
Immunosuppressive drugs 14 (1.5%) 10 (1.4%) 0.7995 5 (0.8%) 8 (1.3%) 0.4028
Gout drugs 59 (6.4%) 86 (11.8%) 0.0001 * 48 (8.0%) 51 (8.5%) 0.753
Potassium preparations 2 (0.2%) 4 (0.5%) 0.2674 1 (0.2%) 0 (0%) 0.3171
Antipsychotics 38 (4.1%) 19 (2.6%) 0.0921 18 (3.0%) 17 (2.8%) 0.8638
Chemotherapeutic drugs 14 (1.5%) 18 (2.5%) 0.1666 11 (1.8%) 9 (1.5%) 0.652
Steroids 57 (6.2%) 43 (5.9%) 0.7995 32 (5.3%) 33 (5.5%) 0.8985
NSAIDs 284 (30.8%) 236 (32.3%) 0.5193 181 (30.1%) 190 (31.6%) 0.5741
Proton pump inhibitors 126 (13.7%) 82 (11.2%) 0.136 77 (12.8%) 75 (12.5%) 0.8622
H2 blockers 120 (13.0%) 144 (19.7%) 0.0002 * 93 (15.5%) 100 (16.6%) 0.5824
Thyroid drugs 12 (1.3%) 13 (1.8%) 0.4301 10 (1.7%) 9 (1.5%) 0.8171
Data are numbers of individuals (%) unless otherwise stated. Abbreviations: ARB; angiotensin II type I receptor blocker, CCB; calcium channel blocker, NSAID; non-
steroidal anti-inflammatory drug. *: p< 0.05 (ARB vs CCB).
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gout, use gout drugs and use H2 blockers than CCB
users. After propensity score matching, the mean age
was 65.5 and 65.6 years, and 37.3% and 37.4% of ARB
users and CCB users were women, respectively.
Table 3 shows laboratory parameters at baseline and
during the exposure period. In ARB users, the mean
values of TC, HbA1c, hematocrit and hemoglobin and
RBC count significantly decreased during the exposureperiod compared with those during the baseline period,
after adjustment for age, sex, medical history and previ-
ous medication. The adjusted mean value of potassium
significantly increased during the exposure period com-
pared with that in the baseline period in ARB users. The
adjusted mean values of TG, glucose, creatinine, sodium,
ALT, AST, GGT and WBC and PLT counts were not sig-
nificantly different during the exposure period compared
with those in the baseline period in ARB users. In CCB
Table 3 Unadjusted and adjusted mean (95% CI) laboratory test values according to ARB or CCB use after propensity score matching
Laboratory
test
ARBs (n = 601) CCBs (n = 601)
Unadjusted Adjusted† Unadjusted Adjusted†
Mean (95%CI) p-value Mean (95%CI) p-value Mean (95%CI) p-value Mean (95%CI) p-value
TG (mmol/L)
baseline 1.65 (1.56, 1.73) 0.5113 1.65 (1.56, 1.73) 0.4846 1.63 (1.56, 1.71) 0.2961 1.63 (1.56, 1.7) 0.2604
exposure 1.60 (1.52, 1.69) 1.6 (1.52, 1.69) 1.57 (1.5, 1.65) 1.57 (1.5, 1.65)
TC (mmol/L)
baseline 5.20 (5.12, 5.28) 0.0056 * 5.2 (5.13, 5.27) 0.0018 * 5.18 (5.1, 5.26) 0.0351 * 5.18 (5.11, 5.25) 0.0206 *
exposure 5.05 (4.97, 5.12) 5.05 (4.98, 5.12) 5.06 (4.98, 5.14) 5.06 (4.99, 5.13)
Blood glucose (mmol/L)
baseline 7.88 (7.63, 8.13) 0.3744 7.88 (7.66, 8.1) 0.3133 7.96 (7.7, 8.23) 0.3809 7.96 (7.72, 8.2) 0.3257
exposure 7.72 (7.47, 7.97) 7.72 (7.5, 7.94) 7.79 (7.53, 8.06) 7.79 (7.55, 8.03)
HbA1c (%)
baseline 6.97 (6.86, 7.08) 0.0451 * 6.97 (6.88, 7.05) 0.0074 * 6.93 (6.81, 7.05) 0.2981 6.93 (6.84, 7.02) 0.1793
exposure 6.81 (6.7, 6.92) 6.81 (6.73, 6.89) 6.84 (6.73, 6.96) 6.84 (6.75, 6.93)
Creatinine (μmol/L)
baseline 72.8 (70, 75.5) 0.2045 72.8 (70.7, 74.8) 0.0934 73.8 (70, 77.7) 0.5707 73.8 (71.3, 76.4) 0.3887
exposure 75.3 (72.5, 78) 75.3 (73.2, 77.3) 75.4 (71.5, 79.2) 75.4 (72.9, 77.9)
Sodium (mmol/L)
baseline 141.4 (141.2, 141.6) 0.1841 141.4 (141.2, 141.6) 0.1725 141.9 (141.7, 142.1)` 0.1137 141.9 (141.7, 142.1) 0.0993
exposure 141.2 (141, 141.4) 141.2 (141, 141.4) 141.7 (141.5, 141.9) 141.7 (141.5, 141.9)
Potassium (mmol/L)
baseline 4.39 (4.36, 4.42) 0.0351 * 4.39 (4.36, 4.42) 0.0241 * 4.3 (4.26, 4.33) 0.8344 4.3 (4.26, 4.33) 0.8298
exposure 4.44 (4.41, 4.47) 4.44 (4.41, 4.47) 4.29 (4.26, 4.32) 4.29 (4.26, 4.32)
ALT (U/L)
baseline 27.2 (25.5, 28.8) 0.0903 27.2 (25.7, 28.6) 0.0577 28.5 (26.4, 30.7) 0.6781 28.5 (26.6, 30.5) 0.6465
exposure 25.2 (23.5, 26.8) 25.2 (23.7, 26.6) 27.9 (25.8, 30) 27.9 (26, 29.8)
AST (U/L)
baseline 27.3 (26, 28.6) 0.3521 27.3 (26.1, 28.4) 0.3041 28.2 (26.4, 30) 0.6099 28.2 (26.6, 29.9) 0.5741
exposure 26.4 (25.1, 27.7) 26.4 (25.2, 27.6) 28.9 (27.1, 30.7) 28.9 (27.2, 30.5)
GGT (U/L)
baseline 53.2 (46.8, 59.6) 0.4179 53.2 (47.1, 59.4) 0.3967 56.1 (49.3, 62.8) 0.7434 56.1 (49.7, 62.5) 0.7292

















Table 3 Unadjusted and adjusted mean (95% CI) laboratory test values according to ARB or CCB use after propensity score matching (Continued)
WBC (x109/L)
baseline 6.36 (6.21, 6.51) 0.8579 6.36 (6.22, 6.5) 0.8494 6.47 (6.32, 6.63) 0.6118 6.47 (6.33, 6.62) 0.5847
exposure 6.34 (6.19, 6.49) 6.34 (6.2, 6.48) 6.42 (6.26, 6.57) 6.42 (6.27, 6.56)
RBC (x1012/L)
baseline 4.36 (4.32, 4.4) 0.0015 * 4.36 (4.33, 4.4) 0.0002 * 4.4 (4.36, 4.45) 0.3324 4.4 (4.36, 4.45) 0.2798
exposure 4.26 (4.22, 4.31) 4.26 (4.23, 4.3) 4.37 (4.33, 4.42) 4.37 (4.33, 4.41)
PLT (x109/L)
baseline 221.2 (216.4, 226) 0.8006 221.2 (216.8, 225.6) 0.7845 222.4 (216.8, 227.9) 0.2089 222.4 (217.2, 227.6) 0.1825
exposure 222.1 (217.3, 226.9) 222.1 (217.7, 226.5) 227.4 (221.9, 233) 227.4 (222.2, 232.6)
Hemoglobin (g/L)
baseline 138.0 (136.7, 139.4) 0.0024 * 138 (136.9, 139.1) 0.0002 * 138.5 (137.1, 139.8) 0.0727 138.5 (137.4, 139.6) 0.0315 *
exposure 135.1 (133.8, 136.5) 135.1 (134, 136.2) 136.7 (135.4, 138.1) 136.7 (135.6, 137.9)
Hematocrit (mmol/mol)
baseline 0.407 (0.404, 0.411) 0.0069 * 0.407 (0.404, 0.411) 0.0012 * 0.409 (0.405, 0.413) 0.285 0.409 (0.406, 0.412) 0.2033
exposure 0.400 (0.396, 0.404) 0.4 (0.397, 0.403) 0.406 (0.402, 0.41) 0.406 (0.403, 0.409)
Abbreviations: TG; triglyceride, TC; total cholesterol, HbA1c; hemoglobin A1c, ALT; alanine aminotransferase, AST; asparate aminotransferase, GGT; γ-glutamyltrasnferase, WBC; white blood cell count, RBC; red blood cell





















Mean (95%CI) p-value Mean (95%CI) p-value
ΔTG (mmol/L)
CCB -0.058 (-0.134, 0.017) 0.7509 -0.067 (-0.139, 0.006) 0.5062
ARB -0.041 (-0.116, 0.035) -0.032 (-0.105, 0.04)
ΔTC (mmol/L)
CCB -0.119 (-0.182, -0.056) 0.4512 -0.123 (-0.185, -0.061) 0.5664
ARB -0.153 (-0.217, -0.09) -0.149 (-0.211, -0.087)
ΔBlood glucose (mmol/L)
CCB -0.17 (-0.439, 0.099) 0.9651 -0.177 (-0.447, 0.093) 0.9085
ARB -0.161 (-0.431, 0.108) -0.154 (-0.424, 0.115)
ΔHbA1c (%)
CCB -0.087 (-0.175, 0.002) 0.2669 -0.089 (-0.175, -0.003) 0.2887
ARB -0.157 (-0.246, -0.069) -0.155 (-0.241, -0.069)
ΔCreatinine (μmol/L)
CCB 1.575 (-0.59, 3.74) 0.5503 1.667 (-0.466, 3.801) 0.6275
ARB 2.508 (0.343, 4.673) 2.416 (0.282, 4.549)
ΔSodium (mmol/L)
CCB -0.24 (-0.462, -0.017) 0.8194 -0.239 (-0.458, -0.019) 0.8275
ARB -0.203 (-0.425, 0.019) -0.204 (-0.424, 0.016)
ΔPotassium (mmol/L)
CCB -0.005 (-0.037, 0.027) 0.0173 * -0.005 (-0.037, 0.027) 0.0182 *
ARB 0.05 (0.018, 0.082) 0.05 (0.018, 0.081)
ΔALT (U/L)
CCB -0.639 (-2.463, 1.185) 0.2966 -0.633 (-2.433, 1.167) 0.2871
ARB -2.012 (-3.835, -0.188) -2.018 (-3.818, -0.218)
ΔAST (U/L)
CCB 0.667 (-0.859, 2.193) 0.1633 0.664 (-0.847, 2.175) 0.1618
ARB -0.867 (-2.393, 0.659) -0.864 (-2.375, 0.647)
ΔGGT (U/L)
CCB 1.599 (-4.675, 7.873) 0.238 1.648 (-4.644, 7.939) 0.2319
ARB -3.74 (-10.015, 2.534) -3.789 (-10.081, 2.502)
ΔWBC (x109/L)
CCB -0.057 (-0.185, 0.072) 0.6864 -0.048 (-0.176, 0.08) 0.8298
ARB -0.019 (-0.148, 0.109) -0.028 (-0.156, 0.099)
ΔRBC (x1012/L)
CCB -0.032 (-0.058, -0.006) 0.0005 * -0.032 (-0.058, -0.006) 0.0004 *
ARB -0.097 (-0.123, -0.072) -0.098 (-0.124, -0.072)
ΔPLT (x109/L)
CCB 5.03 (1.71, 8.35) 0.0825 5.057 (1.793, 8.321) 0.0743
ARB 0.872 (-2.448, 4.192) 0.845 (-2.419, 4.109)
ΔHemoglobin (g/L)
CCB -1.722 (-2.542, -0.903) 0.0476 * -1.721 (-2.538, -0.904) 0.047 *
ARB -2.894 (-3.713, -2.074) -2.895 (-3.712, -2.078)
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Table 4 Unadjusted and adjusted mean changes in laboratory parameters values during0020exposure period from baseline
(Continued)
ΔHematocrit (mmol/mol)
CCB -0.003 (-0.005, -0.001) 0.0103 * -0.003 (-0.005, -0.001) 0.0092 *
ARB -0.007 (-0.01, -0.005) -0.007 (-0.01, -0.005)
Δ indicates mean change in laboratory test value between baseline and exposure period. Abbreviations: TG; triglyceride, TC; total cholesterol, HbA1c; hemoglobin
A1c, ALT; alanine aminotransferase, AST; asparate aminotransferase, GGT; γ-glutamyltransferase, WBC; white blood cell count, RBC; red blood cell count, PLT;
platelet count. *: p< 0.05 (ARB vs CCB). † Analyses were adjusted by covariates including age, sex, medical history and previous drugs.
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significantly decreased during the exposure period com-
pared with those in the baseline period. The adjusted
mean values of TG, glucose, HbA1c, sodium, creatinine,
potassium, ALT, AST, GGT, hematocrit, and WBC, RBC
and PLT counts were not significantly different during
the exposure period compared with those in the baseline
period in CCB users.
Table 4 shows the mean changes in laboratory
parameters during the exposure period compared with
the baseline period. The change in potassium was sig-
nificantly greater in ARB users compared with CCB
users, and the changes in RBC count, hemoglobin and
hematocrit were significantly smaller in ARB users com-
pared with CCB users after adjustment for covariates.
We further analyzed the data divided by sex, because
the standard values of hemoglobin, hematocrit and RBC
count differ by sex. Table 5 shows the mean changes in
laboratory parameters during the exposure period com-
pared with the baseline period after adjustment for
covariates, in subclass analysis. In women, the change in
potassium was significantly greater in ARB users than
in CCB users, and the changes in hemoglobin,
hematocrit and RBC count were significantly smaller in
ARB users than in CCB users. In men, the mean change
in RBC count was significant smaller in ARB users than
in CCB users.
Discussion
In this study, we evaluated and compared the effects of
ARB and CCB monotherapy on biochemical parame-
ters including serum TG, TC, non-fasting blood
glucose, HbA1c, sodium, potassium, creatinine, ALT,
AST and GGT and hematological parameters including
hemoglobin, hematocrit, and WBC, RBC and PLT counts
in patients with mild to moderate hypertension and type
2 diabetes mellitus. We found a significant reduction of
serum TC, HbA1c, hemoglobin, hematocrit and RBC
count in ARB users, and a reduction of serum TC and
hemoglobin level in CCB users, from the baseline period
to during the exposure period. The reductions of RBC
count, hemoglobin and hematocrit in ARB users were
significantly greater than those in CCB users. The in-
crease of serum potassium level in ARB users wassignificantly greater than that in CCB users. These
results suggest that hematological adverse effects and
electrolyte imbalance are greater with ARB monotherapy
than with CCB monotherapy.
It is known that renin-angiotensin system inhibitors,
ACEIs and ARBs, occasionally cause anemia, while having
protective effects on various organs. Valsartan decreases
hematocrit in recipients of kidney transplantation [21].
Losartan decreases hematocrit, hemoglobin and
erythrocyte count in recipients of kidney transplantation
[6,22]. In animals, candesartan decreases hematocrit,
hemoglobin, erythrocyte count, and erythropoietin level in
the rat [23].Confirming these previous reports, our
'real-world' study showed adverse effects of ARB
monotherapy on hemoglobin, hematocrit and RBC
count.
There are some reports that the use of renin-angiotensin
system inhibitors, including ARBs, is associated with
hyperkalemia. The serum level of potassium is significantly
higher in ARB users than in CCB users after renal
transplantation [24]. The relative risk of hyperkalemia was
2-fold higher with dual therapy (ARB plus ACEI) than with
monotherapy (ARB or ACEI) [25]. Use of ARBs and ACEIs
is associated with a high prevalence of hyperkalemia, and
the prevalence of hyperkalemia is significantly higher in
ARB users than in ACEI users [5]. Supporting these previ-
ous reports of hyperkalemia, our study showed that ARB
monotherapy caused electrolyte imbalance with respect to
the serum level of potassium. Our study, in combination
with previous reports, suggested that regular checks of
serum potassium level may be advisable in ARB users.
There are few reports of ARBs affecting hepatic function.
In patients with hypertension and abdominal obesity, there
was no significant difference in the levels of ALT, AST and
GGT between the candesartan group and placebo [26].
There was no significant difference in the levels of ALT and
AST from baseline to six months of use of losartan in
hypertensive diabetic patients [27]. Supporting these
reports, there was no statistically significant difference in
the serum levels of ALT and AST between baseline and the
exposure period in both ARB users and CCB users in our
study. In addition, those changes from baseline to during
the exposure period were not significantly different between
ARB and CCB users. Therefore, the influence of ARB and
Table 5 Adjusted mean changes in laboratory parameters during exposure period from baseline by sex
Laboratory
test
Adjusted Women Adjusted Men
Mean (95%CI) p-value Mean (95%CI) p-value
ΔTG (mmol/L)
CCB -0.076 (-0.178, 0.025) 0.3449 -0.061 (-0.162, 0.039) 0.8484
ARB -0.007 (-0.108, 0.095) -0.047 (-0.148, 0.053)
ΔTC (mmol/L)
CCB -0.127 (-0.239, -0.014) 0.2907 -0.117 (-0.19, -0.044) 0.9665
ARB -0.214 (-0.326, -0.101) -0.115 (-0.188, -0.042)
ΔBlood glucose (mmol/L)
CCB -0.17 (-0.593, 0.253) 0.6908 -0.152 (-0.505, 0.202) 0.8447
ARB -0.293 (-0.717, 0.131) -0.101 (-0.454, 0.252)
ΔHbA1c (%)
CCB -0.075 (-0.216, 0.066) 0.0777 -0.092 (-0.201, 0.016) 0.9247
ARB -0.257 (-0.398, -0.116) -0.1 (-0.208, 0.009)
ΔCreatinine (μmol/L)
CCB 0.475 (-0.776, 1.726) 0.0592 2.346 (-0.967, 5.658) 0.923
ARB 2.202 (0.948, 3.456) 2.578 (-0.73, 5.886)
ΔSodium (mmol/L)
CCB -0.09 (-0.434, 0.254) 0.1124 -0.279 (-0.567, 0.009) 0.3479
ARB -0.49 (-0.835, -0.145) -0.082 (-0.37, 0.206)
ΔPotassium (mmol/L)
CCB -0.015 (-0.067, 0.038) 0.0188 * 0.0002 (-0.041, 0.041) 0.2423
ARB 0.075 (0.023, 0.128) 0.035 (-0.006, 0.076)
ΔALT (U/L)
CCB -0.921 (-3.478, 1.636) 0.1991 -0.31 (-2.767, 2.147) 0.5436
ARB -3.32 (-5.883, -0.758) -1.393 (-3.847, 1.06)
ΔAST (U/L)
CCB 1.125 (-1.37, 3.621) 0.0796 0.59 (-1.334, 2.514) 0.6034
ARB -2.43 (-4.931, 0.072) -0.135 (-2.057, 1.786)
ΔGGT (U/L)
CCB -1.498 (-6.821, 3.824) 0.3965 3.176 (-6.48, 12.832) 0.3908
ARB -4.794 (-10.129, 0.541) -2.839 (-12.482, 6.804)
ΔWBC (x109/L)
CCB -0.092 (-0.278, 0.094) 0.3973 -0.02 (-0.191, 0.152) 0.7449
ARB 0.023 (-0.164, 0.209) -0.06 (-0.232, 0.111)
ΔRBC (x1012/L)
CCB -0.025 (-0.061, 0.012) 0.0004 * -0.032 (-0.067, 0.003) 0.0286 *
ARB -0.12 (-0.157, -0.083) -0.088 (-0.123, -0.053)
ΔPLT(x109/L)
CCB 4.675 (-0.389, 9.738) 0.2057 4.86 (0.551, 9.17) 0.3242
ARB -0.008 (-5.083, 5.067) 1.776 (-2.528, 6.08)
ΔHemoglobin (g/L)
CCB -1.286 (-2.417, -0.156) 0.0135 * -1.811 (-2.931, -0.692) 0.2222
ARB -3.333 (-4.466, -2.2) -2.804 (-3.922, -1.686)
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Table 5 Adjusted mean changes in laboratory parameters during exposure period from baseline by sex (Continued)
ΔHematocrit (mmol/mol)
CCB -0.002 (-0.006, 0.001) 0.0076 * -0.003 (-0.006, 0.0004) 0.0796
ARB -0.009 (-0.012, -0.005) -0.007 (-0.01, -0.004)
Δindicates mean change in laboratory test value between baseline and exposure period. Abbreviations: TG; triglyceride, TC; total cholesterol, HbA1c; hemoglobin
A1c, ALT; alanine aminotransferase, AST; asparate aminotransferase, GGT; γ-glutamyltransferase, WBC; white blood cell count, RBC; red blood cell count, PLT;
platelet count. *: p< 0.05 (ARB vs CCB). † Analyses were adjusted by covariates including age, sex, medical history and previous drugs.
Nishida et al. Cardiovascular Diabetology 2012, 11:53 Page 10 of 12
http://www.cardiab.com/content/11/1/53CCB monotherapy on hepatic function may be minimal
and not of clinical concern.
TC and HbA1c levels in ARB users decreased
during the exposure period compared to the baseline
period in this study. Some ARBs modulate peroxisome
proliferator-activated receptor-γ (PPAR-γ), which regu-
lates lipid metabolism and is associated with insulin
resistance [28,29]. There are some reports that telmisar-
tan, which is a strong modulator of PPAR-γ, has a
favorable effect on glucose metabolism. Telmisartan sig-
nificantly improved HOMA-IR in hypertensive patients
and also significantly decreased HbA1c in type 2 diabetic
patients, especially in those with poor glycemic control
[30]. Treatment with telmisartan significantly improved
the hyper-insulin response to glucose loading in patients
with hypertension and obesity showing insulin resistance
[31]. The favorable effect of ARBs on lipid and glucose
metabolism that we observed may be caused in part by
activation of PPAR-γ. Another reason for the decrease in
HbA1c level in ARB users in our study may be the effect
of the reduction of hemoglobin level. Sinha et al. sug-
gested that both serum hemoglobin and HbA1c levels
are significantly increased in patients with treatment of
iron-deficiency anemia [32]. Ford et al. suggested that
hemoglobin concentration is positively correlated with
the concentration of HbA1c [33]. The effect of ARBs on
the HbA1c level that we observed may have been partly
influenced by the reduction of hemoglobin level.
There was no statistically significant difference in the
level of blood glucose between the baseline and exposure
periods in ARB users; however, we have previously
reported that ARB monotherapy decreases the level of
non-fasting blood glucose during a 6-month exposure
period in non-diabetic patients with hypertension [13].
This discrepancy could be explained in part by differ-
ences in the duration of treatment or history of diabetes
mellitus. It is possible that the glucose-lowering effect
of ARB monotherapy could be weaker in patients with
diabetes mellitus than in non-diabetic patients. We will
evaluate these issues in our next study.
A decrease of TC was also observed in CCB users in
our study. Nakamura et al. reported that CCBs decrease
TC in patients with CKD [34]. Supporting the previous
report, our results revealed a beneficial effect on lipid
metabolism in CCB users in patients with hypertension
and type 2 diabetes mellitus.Subclass analysis showed that the reduction of RBC
count was significantly greater in ARB users than in
CCB users, in both men and women. On the other
hand, the mean changes of potassium, hemoglobin and
hematocrit in women were significantly different
between ARB users and CCB users, but were not sig-
nificantly different in men (Table 5). The reason for this
discrepancy may be as follows. First, the effects of ARBs
on hematological parameters are stronger in patients
with low hemoglobin and hematocrit than in those with
high levels. It is well known that there is a sex difference
in hematological parameters; RBC count, hemoglobin
and hematocrit are generally lower in women than in
men. Second, the effect of ARBs on hemoglobin and
hematocrit may reflect their effects on hormones.
Testosterone is known to increase hemoglobin and
hematocrit [35]. However, the reason for this discrepancy
between women and men is still unclear.
Our study has several limitations. First, the retrospect-
ive and non-randomized nature of the design involved
inherent issues of selection bias and confounding. We
used rigorous statistical methods to balance potential
confounding variables between ARB and CCB users,
including propensity score matching. However, their
ability to control for differences was limited to variables
that were available or measurable. Second, we compared
the effects of ARBs and CCBs in this study. However, the
effects of ARBs on lipid and glucose metabolism slightly
differ among these drugs [36-38], and further studies are
needed to compare the effects of individual drugs. Third,
we did not fix the daily dosage in both ARB and CCB
users, because the achievement of blood pressure goal
requires various doses of an agent across different indivi-
duals or even in the same individual in clinical practice.
This study was not designed to assess the effects of ARBs
and CCBs at each dosage, because it is difficult to
determine whether or not pharmacodynamics are dose-
dependent in clinical settings. However, the findings of
our study, using a sophisticated statistical method in a
real-world setting, are reliable and informative for
clinicians.
Conclusions
In this study, we observed greater reductions of
hemoglobin, hematocrit and RBC count, and a greater
increase of serum potassium level in patients who had
Nishida et al. Cardiovascular Diabetology 2012, 11:53 Page 11 of 12
http://www.cardiab.com/content/11/1/53received ARB monotherapy compared with CCB mono-
therapy. We observed significant differences between
ARB and CCB users, although the mean values of these
parameters remained within normal limits during the
baseline and exposure periods. On the other hand, there
was no significant difference in parameters of lipid me-
tabolism, glucose metabolism and hepatic function and
WBC and PLT counts between ARB and CCB users. Our
findings support the clinical evidence that ARB therapy
is associated with hematological adverse effects and elec-
trolyte imbalance.
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